<DOC>
	<DOC>NCT02024295</DOC>
	<brief_summary>To determine the efficacy and safety S-adenosyl-l-methionine in alcoholic hepatitis with cholestasis.</brief_summary>
	<brief_title>Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis</brief_title>
	<detailed_description>randomize first time for core treatment stage for 6 weeks, then randomized second time for extend treatment for 42 weeks.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Hepatitis, Alcoholic</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Polyene phosphatidylcholine</mesh_term>
	<criteria>Body Mass Index range 1930kg/m2 Alcohol Drinking history more than 5 years, for male ≥ 40g/ day, for female ≥ 20g/ day; STB from 2 to 10X ULN; ALP&gt;1.5X ULN or GGT&gt;3X ULN any one of below, active virus hepatitis, or antiHIV(+) exclude other hepatic disease: nonalcoholic fatty liver, druginduced liver injury, autoimmune hepatitis( AMA/ANA&gt;1:100), Wilson disease, hemochromatosis or other hepatic disease; obstructive cholestasis other nonhepatic diseases caused jaundice primary hepatic carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>